OPV AIDS hypothesis OPV AIDS hypothesis The oral polio vaccine (OPV) AIDS hypothesis posits that the AIDS pandemic originated from live polio vaccines prepared in chimpanzee tissue cultures and then administered to up to one million Africans between 1957 and 1960 in experimental mass vaccination campaigns. Data analyses in molecular biology and phylogenetic studies contradict the OPV AIDS hypothesis; consequently, scientific consensus regards the hypothesis as disproven. The journal "Nature" has described the hypothesis as "refuted". Two vaccines are used throughout the world to combat poliomyelitis. The first polio vaccine, developed by Jonas Salk, is an "inactivated poliovirus vaccine" (IPV), consisting of a
SAV001 a feasible option for an HIV vaccine. Indeed, Jonas Salk developed a therapeutic HIV vaccine in 1987, called Remune now being developed by Immune Response BioPharma, Inc., is based on the killed whole virus approach. Remune vaccine has completed over 25 clinical studies to date and showed a robust mechanism of action restoring white blood cell counts in CD4 & CD8 T cells by reducing viral load and increasing immunity. Also, a group of researchers and professionals in the field of HIV strongly advocates that the killed HIV approach must be taken to fight back the global HIV and AIDS